Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 1
1994 2
1999 1
2001 1
2002 1
2004 1
2007 1
2009 2
2012 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Safety and optimal management of hepatic arterial infusion chemotherapy after pancreatectomy for pancreatobiliary cancer.
Hashimoto A, Nishiofuku H, Tanaka T, Sho M, Anai H, Nakajima Y, Kichikawa K. Hashimoto A, et al. AJR Am J Roentgenol. 2012 Apr;198(4):923-30. doi: 10.2214/AJR.11.6751. AJR Am J Roentgenol. 2012. PMID: 22451562
RESULTS: Placement of the catheter-port system was successful in all patients. Hepatic arterial occlusion and severe asymptomatic hepatic artery stenosis were observed in one patient (2%) and 10 patients (19.6%), respectively. ...
RESULTS: Placement of the catheter-port system was successful in all patients. Hepatic arterial occlusion and severe as …
Randomized controlled trial for the efficacy of hepatic arterial occlusion during radiofrequency ablation for small hepatocellular carcinoma--direct ablative effects and a long-term outcome.
Kobayashi M, Ikeda K, Kawamura Y, Hosaka T, Sezaki H, Yatsuji H, Akuta N, Suzuki F, Suzuki Y, Arase Y, Kumada H. Kobayashi M, et al. Liver Int. 2007 Apr;27(3):353-9. doi: 10.1111/j.1478-3231.2006.01434.x. Liver Int. 2007. PMID: 17355457 Clinical Trial.
The time and energy requirement of RFA of both groups were not significantly different. In addition, no serious adverse effects were observed in both groups. Intrasubsegmental tumour recurrence was found in 0% in group A and 30% in group B at the end of the third year (P=0 …
The time and energy requirement of RFA of both groups were not significantly different. In addition, no serious adverse effects were obse …
Hepatic arterial infusion chemotherapy using percutaneous catheter placement with an implantable port: assessment of factors affecting patency of the hepatic artery.
Seki H, Kimura M, Yoshimura N, Yamamoto S, Ozaki T, Sakai K. Seki H, et al. Clin Radiol. 1999 Apr;54(4):221-7. doi: 10.1016/s0009-9260(99)91155-8. Clin Radiol. 1999. PMID: 10210340 Clinical Trial.
Then, the factors affecting hepatic arterial patency were analysed. RESULTS: Hepatic arterial occlusion was observed in 15 patients (17%). The overall patency of the hepatic artery was 86.9%, 78.4% and 51.5% at 6 months, 1 year and 2 years, respectivel …
Then, the factors affecting hepatic arterial patency were analysed. RESULTS: Hepatic arterial occlusion was observed …
Hepatic arterial infusion chemotherapy for liver metastases from breast cancer.
Arai Y, Sone Y, Inaba Y, Ariyoshi Y, Kido C. Arai Y, et al. Cancer Chemother Pharmacol. 1994;33 Suppl:S142-4. doi: 10.1007/BF00686687. Cancer Chemother Pharmacol. 1994. PMID: 8137476 Clinical Trial.
As a rule, the treatment was performed on an outpatient basis. The side effects and complications observed included myelosuppression (41%), hepatic arterial occlusion (23%), and gastric mucositis (20%), but no major toxicity was encountered. ...
As a rule, the treatment was performed on an outpatient basis. The side effects and complications observed included myelosuppression …
CEUS: a new imaging approach for postoperative vascular complications after right-lobe LDLT.
Luo Y, Fan YT, Lu Q, Li B, Wen TF, Zhang ZW. Luo Y, et al. World J Gastroenterol. 2009 Aug 7;15(29):3670-5. doi: 10.3748/wjg.15.3670. World J Gastroenterol. 2009. PMID: 19653347 Free PMC article.
Among these 172 patients, 16 patients' hepatic artery flow and two patients' portal vein flow was not observed by Doppler ultrasound, and 10 patients' bridging vein flow was not shown by Doppler ultrasound and there was a regional inhomogeneous echo in the liver parenchyma …
Among these 172 patients, 16 patients' hepatic artery flow and two patients' portal vein flow was not observed by Doppler ultrasound, …
Hepatic infarction following abdominal interventional procedures.
Fujiwara H, Kanazawa S, Hiraki T, Mimura H, Yasui K, Akaki S, Yagi T, Naomoto Y, Tanaka N, Hiraki Y. Fujiwara H, et al. Acta Med Okayama. 2004 Apr;58(2):97-106. doi: 10.18926/AMO/32095. Acta Med Okayama. 2004. PMID: 15255511 Free article.
Three episodes followed the elected interventional procedure for hepatocellular carcinoma, and the remaining episode occurred after 12 months of chemoinfusion through an indwelling catheter in the hepatic artery and portal vein. Hepatic arterial occlusion in …
Three episodes followed the elected interventional procedure for hepatocellular carcinoma, and the remaining episode occurred after 12 month …
Surgical repair after bile duct and vascular injuries during laparoscopic cholecystectomy: when and how?
Bachellier P, Nakano H, Weber JC, Lemarque P, Oussoultzoglou E, Candau C, Wolf P, Jaeck D. Bachellier P, et al. World J Surg. 2001 Oct;25(10):1335-45. doi: 10.1007/s00268-001-0120-6. World J Surg. 2001. PMID: 11596900
Patients who were referred several years after LC and who were referred after primary hepaticojejunostomy were included with patients with complicated history (n = 4, group B), and the other patients were included with patients with simple history (n = 11, group A). Simultaneous …
Patients who were referred several years after LC and who were referred after primary hepaticojejunostomy were included with patients with c …
Continuation of regional chemotherapy of hepatic neoplasms despite occlusion of the hepatic artery-report of four cases.
Hildebrandt B, Meyer L, Bechstein WO, Puls R, Arnold D, Bartels B, Stroszczynski C, Neuhaus P, Riess H. Hildebrandt B, et al. Anticancer Drugs. 2002 Jul;13(6):663-9. doi: 10.1097/00001813-200207000-00014. Anticancer Drugs. 2002. PMID: 12172513 Clinical Trial.
Analyzing our experience with this and three other patients with hepatic arterial thrombosis in which we continued HAI, a total of 33 regional treatment courses were applied, containing 5-FU/FA, mitomycin C, doxorubicin or combinations of these drugs. No unexpected toxicities wer …
Analyzing our experience with this and three other patients with hepatic arterial thrombosis in which we continued HAI, a total of 33 region …
Management of patients with unresectable liver metastases from colorectal and gastric cancer employing an implantable port system.
Arai Y, Endo T, Sone Y, Tohyama N, Inaba Y, Kohno S, Ariyoshi Y, Kido C. Arai Y, et al. Cancer Chemother Pharmacol. 1992;31 Suppl:S99-102. doi: 10.1007/BF00687116. Cancer Chemother Pharmacol. 1992. PMID: 1458567 Clinical Trial.
As a rule the treatment was performed on an outpatient basis. The side effects and complications observed included myelosuppression (23%), hepatic arterial occlusion (21%), and gastroduodenal mucositis (12%), although no major toxicity was encountered. …
As a rule the treatment was performed on an outpatient basis. The side effects and complications observed included myelosuppression ( …
The management of patients with advanced carcinoid tumors and islet cell carcinomas.
Moertel CG, Johnson CM, McKusick MA, Martin JK Jr, Nagorney DM, Kvols LK, Rubin J, Kunselman S. Moertel CG, et al. Ann Intern Med. 1994 Feb 15;120(4):302-9. doi: 10.7326/0003-4819-120-4-199402150-00008. Ann Intern Med. 1994. PMID: 8291824 Clinical Trial.
Main outcome measures of response to therapy were rates of tumor regression, rates of improvement in endocrine abnormalities, symptomatic improvement, and duration of favorable response. RESULTS: Objective regressions were observed in 60% of patients treated with occlusion …
Main outcome measures of response to therapy were rates of tumor regression, rates of improvement in endocrine abnormalities, symptomatic im …
12 results